



From left: Benedicte Stavik and Giacomo Roman (project leader). Photo: Jarli&Jordan/University of Oslo.

# Autologous cell-based therapy for coagulation factor deficiencies

Coagulation factor deficiencies are hereditary, monogenic disorders affecting the blood coagulation system, resulting in pathological bleeding or thrombosis. By correcting the disease in the patients' own pluripotent stem cells, we are able to produce autologous, therapeutic tri-dimensional liver organoids. We are set to demonstrate that a single infusion might provide lifelong treatment with no eligibility, toxicity or immune-associated restrictions.

## Application

- Novel cell-based therapy for FVII- and antithrombin deficiency, as proof-of-principle of the technology.

## Market assessment

- Nationally, ~200M NOK in 2022.

## Needs

- Strategic partnerships in academia, innovation and healthcare
- Pre-GMP and pre-clinical phases in the next 3 years
- Further IP and clinical trial

## Competitive advantages

- A novel single dose therapy, designed for long-lasting efficacy with not expected immune reaction.

## IP status

- Patent WO2022101675A1

## Project leader

Giacomo Roman  
giacomo.roman@medisin.uio.no  
Dept. Hematology  
Oslo University Hospital

## Project coordinator

Erlend Ragnhildstveit

## The team:

- Benedicte Stavik, PhD
- Maria E. Chollet, MD, PhD
- Gareth Sullivan, PhD
- Anindita Bhattacharya, PhD
- Knut Lauritzen, PhD
- Christian Qvigstad, MD, PhD
- Per Morten Sandset, MD, PhD

**SPARK**  
— NORWAY —